Bristol-Myers' Phase III CheckMate -498 study misses goal in glioblastoma

9 May 2019

Although approved in a number of cancer indications and bringing significant revenues for US pharma major Bristol-Myers Squibb’s (NYSE: BMY), Opdivo (nivolumab) has seen another trial failure in the hard-to-treat brain cancer glioblastoma.

B-MS today announced the Phase III CheckMate -498 trial evaluating Opdivo plus radiation versus temozolomide plus radiation in patients with newly-diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme (GBM) did not meet its primary endpoint of overall survival (OS) at final analysis.

The safety profile of Opdivo, which generated first-quarter 2019 sales of $1.8 billion, was consistent with previously reported studies in solid tumors. The company will complete a full evaluation of the data from CheckMate -498 and work with investigators on the future presentation and publication of the results. B-MS shares were down more than 1.1% at $46.94 just ahead of mid-day New York trading,

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK